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PRELIMINARY AND SHORT REPORTS
A STUDY OF SOME ANTIHISTAMINE COMPOUNDS BY HISTAMINE
IONTOPHORESIS*
1. OBSERVATIONS ON THE DosE RESPONSE
DAVID L. HEARIN, M.D. AND P.P. Moai, M.D.
Since Fourneau and Bouvet (1) reported in 1933 that certain phenolic ethers were capable
of neutralizing the action of histamine in vitro and in vivo, and Halpern (2) in 1942 reported
his findings on the antihistamine action of Antergan (2339 R P), many studies have been
made of the effect of the antihistamine compounds in human subjects utilizing histamine-
produced erythema and wheals. Many of the reported clinical evaluations have, however,
been inadequately controlled. Several workers (3, 4, 5, 12) have used the electrophoretic
method to introduce histamine into the skin of human subjects. Feinberg (6) has stated
that the usual dosage of Benadryl is 50 mgm. and that some patients may require 100—150
mgm. He gave no evidence for selecting this dosage except clinical observation. We have not
seen reports on antihistamine action as related to increasing dosage of the compound given.
In an attempt to better evaluate the antihistamine action of several compounds given
in increasing dosage we have utilized the method outlined by Perry, Falk and Pillsbury (5).
The compounds used in this study were Benadryl, Pyribenzamine, Hydryllin, Neo anter-
gan and Antistine. For structural formula, mode of action, bibliography, and discussion of
the antihistamine compounds see Woldbott, G. L. (6) and Feinberg, S. M. (7,8). The dosage
schedule for each compound used was as follows:
Benadryl 12.5 mgm., 25 mgm., 50 mgm., 75 mgm., and 100 mgm.
Hydryllin 12.5 mgm., 25 mgm., 50 mgm., 75 mgm. and 100 mgm.
Pyribenzamine 25 mgm., 50 mgm., 75 mgm., and 100 mgm.
Neo Antergan 25 mgm., 50 mgm., 75 mgm., 100 mgm., and 150 mgm.
Antistine 50 mgm., 100 mgm., 150 mgm., and 200 mgm.
PROCEDURE
Ten subjects were used in each dosage schedule for each compound, and of the subjects
used there was a known history of allergy in three. Serial dilutions of histamine acid phos-
phate (Lilly) from 1—800,000 to 1—9,000,000 were used (Chart I). A 2 sq. cm. copper electrode
was used as the positive electrode. A current of two milliamperes was applied for 2 minutes.
The initial histamine threshold determination and a control determination with the buffered
neutral diluent were made on the flexor surface of the forearm. The threshold level was
the highest dilution which produced punctate follicular whealing in the area of the positive
electrode. The dose of the compound being evaluated was then given by mouth. Histamine
threshold determinations were made again at one and two hours after ingestion of the com-
pound. The maximum threshold elevation was obtained at either the one or two hour de-
termination. If, however, the two hour determination showed a further elevation of the
threshold, a three hour determination was made, but in no instance was there any further
elevation of the threshold at the three hour determination. All threshold determinations
were then converted to their corresponding histamine values and the difference between
the initial histamine threshold and the maximum histamine threshold for each subject was
calculated. The response of the subjects, to the same compound, showed marked variations,
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for example, with 50 mgm. of Benadryl one subject might neutralize .500 micrograms of
histamine and another would neutralize .750 micrograms and still another .250 micrograms.
The average histamine neutralization value was taken from the ten subjects in each dosage
schedule for the compounds studied. The results are shown in Graph I and Chart II. From
the graph we made the following observations:
1. Benadryl, Pyribenzamine, and Hydryllin show similar types of curves and their anti-
histamine values in corresponding dosage show only slight differences.
2. The antihistamine value of 50 mgm. of Benadryl and of Pyribenzamine is greater than
that of 100 mg. of each. 100 mgm. of Hydryllin is slightly more active than 50 xngm. 12.5
mgm. of this compound also shows appreciable antihistamine activity.
CHART II
Amount of histamine neutralized in micrograms/cc.
moo 12.5 MGM. 25 MOM. 50 MOM. 75 MOM. 100 MOM. 150 MOM. 200 MOM.
Benadryl
Pyribenzamine
Hydryllin
Antistine
Neo Antergan
180
372
.246
.126
.206
.042
.743
.658
.644
.120
.075
.301
.431
.309
.270
.628
.421
.814
.156
.325
.360
.431
.196
CHART III
Number of subjects noting side effects
DRUO 12.5 MOM. 25 MOM. 50 MGM. 75 MOM. 100 MOM. 150 MOM. 200 MOM.
Benadryl
Pyribenzamine
Hydryllin
Neo Antergan
Antistine
0
0
0
—
—
0
0
0
0
—
2
1
1
0
0
4
1
2
0
—
6
4
4
0
0
3
0 0
3. Neo Antergan shows increasing activity with increasing dosage but even 150 mgm
was still less active than 50 mgm. of Benadryl, Pyribenzamine or Hydryllin. This is in con-
trast to the report of Rose (9) who stated that Neo Antergan was a more potent antihist-
aminic than Benadryl.
4. Antistine shows more antihistamine activity in the 150 mgm. dose but was still less
active than any of the other compounds studied.
5. While a study of side or toxic effect was not a planned part of the study, we did note
the side effect if the subject remarked about it. Chart III. There was increasing incidence
of side effect with the 75 mgm. and 100 mgm. dose of Benadryl, Pyribenzamine and Hydryl-
un. Other workers (10, 11) have also noted an increase in side effect with increasing dosage.
Neo Antergan produced no side effect except in the 150 mgm. dose. No subjects noted side
effect with Antistine. The side effects noted were drowsiness, dizziness and nausea in order
of decreasing frequency.
CONCLUSIONS
1. Histamine iontophoresis is superior to other methods of evaluating antihistamine
compounds in human subjects.
2. Of the compounds studied, Benadryl and Pyribenzamine are most active when given
in a single dose of .50 mgm.
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3. 50 mgm. of Hydryllin is only slightly less active than 100mgm. when given in a single
dose.
4. Neo Antergan and Antistine show less antihistamine activity than the other com-
pounds studied.
5. There was definite increase in side effect with increasing dosage in all compounds
studied except antistine.
6. There was marked variation in individual response to the different compounds studied.
7. It is believed that Benadryl, Pyribenzamine and Hydryllin should be given in 50
mgm. dose preferably every 2—3 hours for best antihistamine activity, but individual vari-
ations must be taken into consideration.
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